Table I.

Prognostic value of the expression levels of CCR genes in early-stage pancreatic ductal adenocarcinoma using The Cancer Genome Atlas database.

		Overall survival
Gene expression level	Patients (n=112)	Number of events	Median survival time (days)	Crude HR (95% CI)	Crude Log-rank P-value	Adjusted HR (95% CI)	Adjusted P-valuea
CCR1
Low	56	34	485	1		1
High	56	35	592	0.820 (0.508–1.326)	0.418	0.812 (0.474–1.393)	0.450
CCR2
Low	56	38	458	1		1
High	56	31	603	0.518 (0.317–0.846)	0.007	0.668 (0.379–1.178)	0.163
CCR3
Low	56	33	511	1		1
High	56	36	518	0.854 (0.527–1.385)	0.521	0.947 (0.556–1.613)	0.841
CCR4
Low	56	40	470	1		1
High	56	29	607	0.490 (0.299–0.804)	0.004	0.601 (0.343–1.054)	0.076
CCR5
Low	56	39	393	1		1
High	56	30	603	0.433 (0.263–0.714)	0.001	0.478 (0.269–0.852)	0.012
CCR6
Low	56	39	458	1		1
High	56	30	596	0.539 (0.329–0.882)	0.013	0.527 (0.299–0.927)	0.026
CCR7
Low	56	38	473	1		1
High	56	31	592	0.562 (0.344–0.918)	0.020	0.630 (0.360–1.102)	0.105
CCR8
Low	56	38	470	1		1
High	56	31	603	0.588 (0.362–0.955)	0.030	0.642 (0.372–1.107)	0.111
CCR9
Low	56	37	485	1		1
High	56	32	568	0.621 (0.381–1.014)	0.054	0.374 (0.209–0.670)	0.001
CCR10
Low	56	40	481	1		1
High	56	29	634	0.750 (0.462–1.217)	0.242	0.835 (0.491–1.422)	0.507

^aAdjusted for histological grade, radiation therapy, radical resection and targeted molecular therapy using the multivariate Cox proportional hazards regression model. CCR, C-C motif chemokine receptor; HR, hazard ratio; CI, confidence interval.